Sam Moussa
Specialist
2585 N Wyatt Dr
Tucson, AZ 85712
Who else practices at this address →
Pima County includes primary care (34% of residents) and dental (4% of residents) and mental health (14% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 19
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Specialist primary
AZ license 19323
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 19
- Services billed
- 28
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| New patient office or other outpatient visit, 45-59 minutes | 33 | 33 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $2,881 in total to this clinician.
| Olympus America Inc. | $2,881 |
|---|
| Debt forgiveness | $2,881 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Olympus America Inc. Mar 31, 2025 | Debt forgiveness Single Use Repositionable Clip · Endotherapy · in-kind | $2,881 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $1,697,922 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
Madrigal Pharmaceuticals · Active, not recruiting · NCT03900429 - A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT05519475 - A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fib…
AstraZeneca Pharmaceuticals LP - A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
Madrigal Pharmaceuticals · Active, not recruiting · NCT04951219 - A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepati…
Boehringer Ingelheim International GmbH - A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/…
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.